Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
05 2022
Historique:
received: 05 04 2021
accepted: 23 04 2021
pubmed: 11 5 2021
medline: 1 9 2022
entrez: 10 5 2021
Statut: ppublish

Résumé

While urinary incontinence (UI) commonly occurs after radical prostatectomy (RP), it is unclear what factors increase the risk of UI development. To perform a systematic review of patient- and tumour-related prognostic factors for post-RP UI. The primary outcome was UI within 3 mo after RP. Secondary outcomes included UI at 3-12 mo and ≥12 mo after RP. Databases including Medline, EMBASE, and CENTRAL were searched between January 1990 and May 2020. All studies reporting patient- and tumour-related prognostic factors in univariable or multivariable analyses were included. Surgical factors were excluded. Risk of bias (RoB) and confounding assessments were performed using the Quality In Prognosis Studies (QUIPS) tool. Random-effects meta-analyses were performed for all prognostic factor, where possible. A total of 119 studies (5 randomised controlled trials, 24 prospective, 88 retrospective, and 2 case-control studies) with 131 379 patients were included. RoB was high for study participation and confounding; moderate to high for statistical analysis, study attrition, and prognostic factor measurement; and low for outcome measurements. Significant prognostic factors for postoperative UI within 3 mo after RP were age (odds ratio [OR] per yearly increase 1.04, 95% confidence interval [CI] 1.03-1.05), membranous urethral length (MUL; OR per 1-mm increase 0.81, 95% CI 0.74-0.88), prostate volume (PV; OR per 1-ml increase 1.005, 95% CI 1.000-1.011), and Charlson comorbidity index (CCI; OR 1.28, 95% CI 1.09-1.50). Increasing age, shorter MUL, greater PV, and higher CCI are independent prognostic factors for UI within 3 mo after RP, with all except CCI remaining prognostic at 3-12 mo. We reviewed the literature to identify patient and disease factors associated with urinary incontinence after surgery for prostate cancer. We found increasing age, larger prostate volume, shorter length of a section of the urethra (membranous urethra), and lower fitness were associated with worse urinary incontinence for the first 3 mo after surgery, with all except lower fitness remaining predictive at 3-12 mo.

Identifiants

pubmed: 33967010
pii: S2405-4569(21)00126-7
doi: 10.1016/j.euf.2021.04.020
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

674-689

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Michael Lardas (M)

Department of Urology, Metropolitan General Hospital, Athens, Greece. Electronic address: lardamk@gmail.com.

Nikos Grivas (N)

Department of Urology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, Greece.

Thomas P A Debray (TPA)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Fabio Zattoni (F)

Urology Unit, Santa Maria della Misericordia University Hospital, Udine, Italy.

Christopher Berridge (C)

Worcestershire Acute Hospitals NHS Trust, Redditch, UK.

Marcus Cumberbatch (M)

Academic Urology Unit, University of Sheffield, Sheffield, UK.

Thomas Van den Broeck (T)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Erik Briers (E)

Patient Advocate, Hasselt, Belgium.

Maria De Santis (M)

Department of Urology, Charité Universitätsmedizin Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.

Andrea Farolfi (A)

Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy.

Nicola Fossati (N)

Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Giorgio Gandaglia (G)

Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Silke Gillessen (S)

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.

Shane O'Hanlon (S)

Medicine for Older People, Saint Vincent's University Hospital, Dublin, Ireland.

Ann Henry (A)

Leeds Cancer Centre, St. James's University Hospital and University of Leeds, Leeds, UK.

Matthew Liew (M)

Department of Urology, Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, UK.

Malcolm Mason (M)

Division of Cancer & Genetics, Cardiff University School of Medicine, Velindre Cancer Centre, Cardiff, UK.

Lisa Moris (L)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Daniela Oprea-Lager (D)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands.

Guillaume Ploussard (G)

La Croix du Sud Hospital, Quint Fonsegrives, France.

Olivier Rouviere (O)

Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Ivo G Schoots (IG)

Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Theodorus van der Kwast (T)

Department of Pathology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Henk van der Poel (H)

Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Thomas Wiegel (T)

Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.

Peter-Paul Willemse (PP)

Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands.

Cathy Y Yuan (CY)

Department of Medicine, Health Science Centre, McMaster University, Hamilton, ON, Canada.

Jeremy P Grummet (JP)

Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia.

Derya Tilki (D)

Martini-Klinik Prostate Cancer Center, and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Roderick C N van den Bergh (RCN)

Department of Urology, Antonius Hospital, Utrecht, The Netherlands.

Thomas B Lam (TB)

Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.

Philip Cornford (P)

Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK.

Nicolas Mottet (N)

Department of Urology, University Hospital, St. Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH